Abstract
Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by progressive degeneration of motor neurons which leads to muscular atrophy, paralysis and death in 3-5 years from starting symptoms. This disorder is accompanied by noteworthy spinal inflammation mediated in particular by microglia and mast cells. No effective therapy is available. This report describes the effects of administering the anti-inflammatory agent palmitoylethanolamide in a case of sporadic amyotrophic lateral sclerosis. Palmitoylethanolamide treatment led to an improved clinical picture, as evidenced by electromyographic analysis and pulmonary function. Conceivably, the action of palmitoylethanolamide could result, in part, from its ability to dampen mast cell and microglia activation.
Keywords: Mast cells, microglia, motor neuron disease, neurodegeneration, electromyography, spinal inflammation, palmitoylethanolamide, dampen mast cell, microglia activation, pulmonary function
CNS & Neurological Disorders - Drug Targets
Title:Amyotrophic Lateral Sclerosis Treatment with Ultramicronized Palmitoylethanolamide: A Case Report
Volume: 11 Issue: 7
Author(s): Simonetta Clemente
Affiliation:
Keywords: Mast cells, microglia, motor neuron disease, neurodegeneration, electromyography, spinal inflammation, palmitoylethanolamide, dampen mast cell, microglia activation, pulmonary function
Abstract: Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by progressive degeneration of motor neurons which leads to muscular atrophy, paralysis and death in 3-5 years from starting symptoms. This disorder is accompanied by noteworthy spinal inflammation mediated in particular by microglia and mast cells. No effective therapy is available. This report describes the effects of administering the anti-inflammatory agent palmitoylethanolamide in a case of sporadic amyotrophic lateral sclerosis. Palmitoylethanolamide treatment led to an improved clinical picture, as evidenced by electromyographic analysis and pulmonary function. Conceivably, the action of palmitoylethanolamide could result, in part, from its ability to dampen mast cell and microglia activation.
Export Options
About this article
Cite this article as:
Clemente Simonetta, Amyotrophic Lateral Sclerosis Treatment with Ultramicronized Palmitoylethanolamide: A Case Report, CNS & Neurological Disorders - Drug Targets 2012; 11 (7) . https://dx.doi.org/10.2174/1871527311201070933
DOI https://dx.doi.org/10.2174/1871527311201070933 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry Modulation of Endoplasmic Reticulum Stress: An Opportunity to Prevent Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Potential of Photobiomodulation to Induce Differentiation of Adipose- Derived Mesenchymal Stem Cells into Neural Cells
Current Stem Cell Research & Therapy Mitochondria: Prospective Targets for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design Assessing Glutamatergic Function and Dysfunction in Peripheral Tissues
Current Medicinal Chemistry β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Advances in Studies on Neurodegenerative Diseases and their Treatments
Current Topics in Medicinal Chemistry siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design Regulation of Neuronal Cell Death and Neurodegeneration by Members of the Bcl-2 Family: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders Interactions of VDAC with Proteins Involved in Neurodegenerative Aggregation: An Opportunity for Advancement on Therapeutic Molecules
Current Medicinal Chemistry Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Current Alzheimer Research PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration
Current Alzheimer Research Functional Switch From Pro-Neurotrophins to Mature Neurotrophins
Current Protein & Peptide Science Genetics of Alzheimer's Disease and Frontotemporal Dementia
Current Molecular Medicine Subcellular Injuries in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Synthetic Methods for the Preparation of Triazepandiones and Review of their Applications
Current Organic Chemistry Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry The Use of Stem Cells for the Treatment of Spinal Surgical Conditions.
Current Stem Cell Research & Therapy Commentary (Changes of Synaptic Plasticity in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets